Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
Abstract The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, including those who experienced grade...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | англи |
| Хэвлэсэн: |
2016
|
| Онлайн хандалт: | https://doi.org/10.1158/2326-6066.cir-15-0193 https://cancerimmunolres.aacrjournals.org/content/canimm/4/4/345.full.pdf |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Хамгийн түрүүнд сэтгэгдэл үлдээх!